Michael Hayden joins Med BioGene's board
This article was originally published in Clinica
Executive Summary
Canadian molecular diagnostics specialist Med BioGene has appointed Michael Hayden to its board of directors. Dr Hayden is a professor of medical genetics at the University of British Columbia, Vancouver, Canada, and director of a genetic research facility there, the Center for Molecular Medicine and Therapeutics. He has also served as the scientific director of the Canadian Genetic Diseases Network since it was founded in 1990, and is director and chief scientific officer of Xenon Pharmaceuticals, a privately-held biotech company. Vancouver-based Med BioGene's lead product is LungExpress Dx, a test to help improve staging for non-small cell lung cancer patients, identifying patients with a higher risk of mortality. The firm hopes to launch it in the US this year.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.